1
Return

Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma

delete2026-06-20
delete0
delete
OA
AI
J
Jacopo D’Argenzio
N
Nicolò Rampi
J
Jacopo Pozzi *
V
Valentina Vespro
M
Matilde Pavan
E
Elena Casiraghi
F
Francesca G. Rossi
A
Angelo Castello
L
Laura. V. Forzenigo
M
Massimo Castellani
M
Massimo Zilocchi
F
Francesco Passamonti
G
Gianpaolo Carrafiello
DOI:10.1007/s11547-026-02233-wdelete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
To evaluate whether baseline splenic ^18F-FDG PET uptake and CT-derived spleen volume predict early progression (≤ 36 months) and progression-free survival (PFS) in diffuse large B cell lymphoma (DLBCL), and whether they interact. Retrospective cohort of adults with newly diagnosed DLBCL undergoing baseline ^18F-FDG PET/CT and CT. Splenic PET positivity was defined visually (uptake exceeding hepatic background); spleen volume was measured semi-automatically. Early progression/relapse was analysed as a 36-month milestone endpoint and PFS as time-to-event. Multivariable logistic and Cox models included IPI, sex, treatment, splenic PET, spleen volume, and a PET × volume interaction. A prespecified PFS sensitivity analysis re-included event-free patients censored before 36 months. 124 patients were included (68 men; median age 68 years [IQR 57–77]); 45/124 (36.3%) were PET-positive; median spleen volume was 3.13 dL (IQR 1.92–5.79). IPI predicted ≤ 36-month progression (OR 1.52; p = 0.021) and PFS (HR 1.44; p = 0.004). Splenic PET positivity predicted ≤ 36-month progression (OR 2.83; p = 0.048) but not PFS (p = 0.103). The PET × volume interaction was significant (OR 0.70; p = 0.021; HR 0.81; p = 0.033). In PET-negative patients, larger spleen volume predicted higher risk (OR 1.42; p = 0.027; HR 1.22; p = 0.042), whereas volume was neutral in PET-positive cases. In the PFS sensitivity analysis (N = 145), the interaction attenuated (HR 0.83; p = 0.057) and the PET-negative volume effect was borderline (HR 1.21; p = 0.053). Splenic PET positivity is a dominant risk marker in DLBCL in this cohort. CT-derived spleen volume may add conditional prognostic information in PET-negative patients, but the incremental value of the PET × volume interaction is modest and requires external validation.
Keywords:
Spleen
Diffuse large B cell lymphoma
Positron emission tomography
Computed tomography
Prognostic Biomarkers

Journal

La radiologia medica cover
La radiologia medica
IF:
4.8
Papers:
206
Citations:
0

Organization

P
Postgraduate School in Radiodiagnostics
Scholars:
13
Papers: 5
Citations: 0
N
nuclear medicine department
Scholars:
114
Papers: 50
Citations: 0
R
radiology department
Scholars:
396
Papers: 223
Citations: 1
U
università degli studi di milano
Scholars:
823
Papers: 318
Citations: 0
H
hematology department
Scholars:
386
Papers: 116
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers